FDA Updates on Antimicrobial Product Guidelines and Regulatory Strategy Implications
The US Food and Drug Administration continues to refine its regulatory framework for antimicrobial products amid accelerating antimicrobial resistance and shifting clinical development realities. Recent updates to antimicrobial product guidelines signal a more risk-based, pathogen-focused approach that aligns with modern microbiology, adaptive trial design, and evolving stewardship expectations. For biotechnology companies and pharmaceutical developers, these … Read more